Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in XXXX .

@entity1 @entity2994
PURPOSE: To assess changes in retinal nonperfusion (RNP) in @entity1 with @entity2994 ( @entity2994 ) treated with ranibizumab. DESIGN: Secondary outcome measure in randomized double-masked controlled clinical trial. @entity1 : Thirty-nine @entity1 with central @entity2994 (CRVO) and 42 with branch @entity2994 (BRVO). METHODS: Subjects were randomized to 0.5 or 2.0 mg ranibizumab every month for 6 months and then were re-randomized to pro re nata (PRN) groups receiving either ranibizumab plus scatter laser photocoagulation or ranibizumab alone for an additional 30 months. MAIN OUTCOME MEASURES: Comparison of percentage of @entity1 with increased or decreased area of RNP in @entity1 with @entity2994 treated with 0.5 versus 2.0 mg ranibizumab, during monthly injections versus ranibizumab PRN, and in @entity1 treated with ranibizumab PRN versus ranibizumab PRN plus laser. RESULTS: In @entity2994 @entity1 given monthly injections of 0.5 or 2.0 mg ranibizumab for 6 months, there was no significant difference in the percentage who showed reduction or increase in the area of RNP. However, regardless of dose, during the 6-month period of monthly injections, a higher percentage of @entity1 showed a reduction in area of RNP and a lower percentage showed an increase in area of RNP compared with subsequent periods of ranibizumab PRN treatment. After the 6-month period of monthly injections, BRVO @entity1 , but not CRVO @entity1 , randomized to ranibizumab PRN plus laser showed significantly less progression of RNP compared with @entity1 treated with ranibizumab PRN. CONCLUSIONS: Regardless of dose (0.5 or 2.0 mg), monthly ranibizumab injections promote improvement and reduce progression of RNP compared with PRN injections. The addition of scatter photocoagulation to ranibizumab PRN may reduce progression of RNP in @entity1 with BRVO, but a statistically significant reduction was  not seen in @entity1 with CRVO.
